Clinical Trials and Research

AbstractBackground Cardiac amyloidosis (CA) is frequently preceded by soft tissue infiltration, manifesting as orthopaedic "red flags" such as carpal tunnel…

AbstractInterpreting composite endpoints in cardiovascular drug development is a key challenge, particularly when events of different clinical relevance are…

Long-term treatment with diflunisal may help slow disease progression in people with hereditary transthyretin amyloidosis (hATTR), according to a Swedish real-world…

AbstractCardiac amyloidosis is a clinical condition characterized by deposition of amyloid fibrils in the myocardium, leading to increased left ventricular wall…

In transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM), high left ventricular (LV) amyloid load is associated with cardiac dysfunction, including worse global…

AbstractBackground: Cardiac Amyloidosis (CA), specifically Transthyretin Amyloid Cardiomyopathy (ATTR-CM), is an under-recognized, progressive, and fatal disease.…

AbstractIn a first-in-human trial (NI006-101), the monoclonal antibody cliramitug, targeting misfolded transthyretin, demonstrated a favorable safety profile and…

Brief SummaryThis study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in participants with a…

Trial Purpose and DescriptionThis is a Phase I/II, multi-center, open-label study designed to evaluate the safety, tolerability and efficacy of elranatamab in…

For East Asian adults with transthyretin amyloid cardiomyopathy (ATTR-CM), the approved therapy Amvuttra (vutrisiran) is a safe and effective treatment, with…